We describe a 42-year-old male, 2 years post unrelated allogeneic stem cell transplantation (SCT) for chronic myeloid leukaemia, who developed pertussis following an outbreak in the local community. The incidence of pertussis is rising owing to waning immunity and lack of immunisation of children between 2 and 7 years of age. Data from older adults suggest considerable morbidity in immunocompetent individuals owing to bordetella pertussis. The development of a highly effective acellular vaccine for bordetella pertussis, as recently described, may allow protective immunisation to be included in the post transplant vaccination schedule for patients.
Bordetella pertussis is a highly infectious Gram-negative coccobacillus, which may cause respiratory tract infection. Infections may be asymptomatic, mildly symptomatic or classic in presentation; classic features include a 21-day paroxysmal cough, vomiting and associated risk of morbidity and mortality in infants. Most cases occur in children under age 5, and vaccination is not licensed in the UK for children above 7 years of age. Epidemiological surveillance for transmissible infections in England and Wales has, however, shown an increase in the incidence of pertussis infections since 1995, 1 with data also demonstrating increasing evidence of disease prevalence in older children and adults. 2 The increasing incidence of pertussis may be due to reduction in vaccination rates of children between 2 and 7, and increased recognition of disease in older children and adult populations, contributing to the disease reservoir and spread.
Most adult cases are not suspected, detected and reported. A recent study confirmed the incidence of pertussis among adults between 15 and 65 years, 370 cases per 100 000 person-years, and estimated that 0.7-5.7% of prolonged coughs are caused by pertussis. 3 Additionally, there may be evidence that clinical severity of pertussis in adults increases with age. 4 The effect of age on the clinical presentation of pertussis was assessed in 664 adolescent and adult cases. Complications were more frequent in adults than in adolescents (28 vs 16%). Pneumonia occurred in 2% of patients o30 years old but in 5-9% of older patients. Among adults X50 years old, 6% were hospitalised, with a mean duration of stay of 17 days, versus a mean of 3 days for patients o50 years old. Secondary case patients had milder disease than index case patients, but most had the classic symptomatology. 5 We report a 42-year-old male who underwent matched unrelated donor PBSCT for chronic myeloid leukaemia in accelerated phase, conditioned by cyclophosphamide (120 mg/kg) and TBI 14.4 Gy. At 3 months post transplant, he developed grade II acute skin and gut GvHD, both steroid responsive. Subsequently, he developed limited cutaneous chronic GvHD, but was able to discontinue cyclosporine by 15 months post transplant. He did not receive his vaccinations 1 year post transplant as he was on immunosuppressants. Two years post transplant, he attended with a dry cough, malaise and a characteristic whoop. His 10-year-old daughter had been recently diagnosed and treated for whooping cough, following a documented local outbreak at school. The diagnosis was confirmed by culture. He was treated as an index case with erythromycin for 14 days, and remained symptomatic with classic features of severe paroxysmal cough and occasional vomiting for 4 weeks; however, he did not develop any respiratory compromise or require hospitalisation. Local public health authorities have confirmed an increased incidence of bordetella pertussis infection within the region (Figure 1 ), affecting both infants and older children and this is in keeping with reported trends for pertussis infection nationally.
EBMT guidelines on vaccinations do not currently recommend vaccination against bordetella pertussis for patients above the age of 7 years. 6 There is no reported case of severe or fatal pertussis infection after SCT in adults and no data regarding vaccine efficacy for this disease. Acellular pertussis immunisation post transplant is recommended by the Royal College of Paediatrics and Child Health, for immunocompetent children. 7 The prevalence of the disease being predominantly in children and the fact that neonates experience highest mortality risk is a possible reason behind this. A recent randomised study demonstrated that influenza vaccination plays an important role in protecting BMT recipients against influenza with an efficacy of 80%, emphasising the importance of good compliance with vaccination. 8 The rising trend in the incidence and localised outbreaks of pertussis, as described above, suggests that the current vaccination schedule for infants may not be sufficient to provide herd immunity. Data from older adults suggest considerable morbidity in immunocompetent individuals owing to bordetella pertussis. The development of a highly effective acellular vaccine for bordetella pertussis, as recently described, 3 may allow protective immunisation to be included in the post transplant vaccination schedule for patients. Trials to determine the efficacy of such vaccinations in a post transplant setting would be helpful to determine and confirm their role in avoiding considerable morbidity due to this pathogen. G Kochethu, FJ Clark and CF Craddock Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK E-mail: geothy@yahoo.com
